These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15351154)

  • 1. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?
    Montalescot G
    Eur Heart J; 2004 Sep; 25(18):1562-4. PubMed ID: 15351154
    [No Abstract]   [Full Text] [Related]  

  • 2. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Pereira H;
    Rev Port Cardiol; 2001 Jun; 20(6):687-8. PubMed ID: 11525077
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction.
    O'Shea C; Tcheng JE
    J Invasive Cardiol; 1999 Aug; 11(8):494-9. PubMed ID: 10745582
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa inhibitors and the guidelines for treatment of non-ST-elevation myocardial infarction.
    Coplan NL
    J Am Coll Cardiol; 2004 Mar; 43(5):926-7; author reply 927-8. PubMed ID: 14998642
    [No Abstract]   [Full Text] [Related]  

  • 5. Earlier administration of high-dose bolus tirofiban in STEMI increases benefit without increasing bleeding complications.
    Cardiovasc J Afr; 2009; 20(4):268. PubMed ID: 19701545
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence.
    Singh S; Gopal AK; Bahl VK
    Indian Heart J; 2005; 57(3):201-9. PubMed ID: 16196176
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G; Marino P
    Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current strategies with high-dose tirofiban.
    Mukherjee D; Roffi M
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose, bolus-only, glycoprotein IIb/IIIa inhibitors for elective coronary intervention: logical, safe, cost-effective, and it works!
    Fischell TA
    J Invasive Cardiol; 2008 Feb; 20(2):59-60. PubMed ID: 18252968
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction in a tertiary referral medical center in a developing country.
    Abdallah M; Karrowni W; Dakik HA
    Int J Cardiol; 2007 Jan; 114(2):282-3. PubMed ID: 16581145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPIIb/IIIa inhibitor-induced dethrombosis.
    Furman MI; Frelinger AL; Michelson AD
    J Thromb Thrombolysis; 2004 Aug; 18(1):11-7. PubMed ID: 15744548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.
    Schneider DJ; Aggarwal A
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction.
    Martinez-Ojeda J; Martinez-Toro J
    Bol Asoc Med P R; 2005; 97(4):308-14. PubMed ID: 16599071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit.
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):498-9. PubMed ID: 18819148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.